Everything you need to win Avalo Therapeutics — in one platform.
Who to reach, what to say, and why now on Avalo Therapeutics — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Avalo Therapeutics — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
The decision-maker’s email and mobile — dial in-browser.
Avalo Therapeutics Receives $69.4 Million from Full Exercise of Private Placement Warrants
Nov 12, 2024•over 1 year ago
Contract Type
partnership
RockvilleBiotechnologyHealth CareTherapeutics
Description
Avalo Therapeutics, Inc. has received $69.4 million in gross proceeds from the full exercise of the warrants issued in a March 2024 private placement. The warrants were exercised at an exercise price of $5.796933 per underlying share of common stock, resulting in the issuance of 781,259 shares of common stock and 11,186.267 shares of series C non-voting convertible preferred stock.
Company Information
Company
Avalo Therapeutics
Location
Rockville, Maryland, United States
About
Avalo Therapeutics is a leading clinical-stage biopharmaceutical company that employs a precision medicine approach to discover, develop, and commercialize targeted therapeutics for patients with significant unmet clinical need.
RockvilleBiotechnologyHealth CareTherapeutics